Type 2 diabetes
Conditions
Interventions
dulalutide for 24 weeks
semaglutide for 24 weeks
Sponsors
Kawasai Medical School
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: Men and women over 20 years old at the time of consent acquisition Patients with HbA1c of 7.0% or more and less than 10.0% at the time of consent, who the attending physician considers to require new treatment with a GLP-1 receptor agonist HbA1c levels 12 weeks prior to the start of treatment in this study are available and recorded Patients who have received sufficient explanation before participating in this study, and who have fully understood and consented to the document by their own free will. Patients who have not started a new diabetes drug or changed the dose for 12 weeks until consent is obtained
Exclusion criteria
Exclusion criteria: Type 1 diabetes patient Patients using insulin Patients treated with GLP-1 receptor agonist within 3 months Patients with a history of severe ketosis, diabetic coma, or precoma within the last 6 months Pregnant or potentially pregnant women and lactating patients Diabetic patients with specific mechanisms and diseases (exocrine pancreatic disease, endocrine disease, drug-induced, hereditary) Cases during steroid administration Patients with malignant tumors Patients with severe infections, before and after surgery, and with serious trauma Patients with severe liver damage Other cases judged to be inappropriate
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Comparison of HbA1c levels between the two groups 6 months after the start of administration. | — |
Countries
Japan
Contacts
Public ContactTomohiko Kimura
Kawasai Medical School Diabetes obesity and metabolism
Outcome results
None listed